**To the Editor:** We read with interest the article by Martens et al., which analyzed the frequency of macrolide resistance--mediating mutations in *Mycoplasma genitalium* infections in the southeastern region of the Netherlands during 2014--2017 ([@R1]). The authors reported high rates of macrolide resistance in *M. genitalium* infections (281/827; 34.0%) and observed a decrease in the rate in 2017 (115/290; 39.7%) compared with 2016 (92/207; 44.4%), after an increase in the number of tests of cure performed.

Increasing rates of macrolide resistance in *M. genitalium* are a problem not only in the Netherlands but also worldwide: 77.4% in New Zealand ([@R2]) and 41% in the United Kingdom ([@R3]). Macrolide resistance in *M. genitalium* as a consequence of single-dose azithromycin treatment has been previously reported ([@R4]). European Academy of Dermatology and Venereology guidelines recommend azithromycin in an extended regimen (500 mg day 1, 250 mg days 2--5, orally) as a first-line treatment, followed by a test of cure 4--6 weeks after treatment ([@R5]).

In northern Spain, local protocols for the treatment of *M. genitalium* infections are based on the European guideline. We performed a prospective/retrospective study during August 2015--October 2018. We confirmed 173 cases of *M. genitalium* infection; mean patient age was 29.4 years, and 57.2% (99/173) were male. We found macrolide-resistant *M. genitalium* strains in 21.8% (27/124) patients, which is a lower rate than was found in the Netherlands. Most of the patients attending posttreatment follow-up showed wild-type *M. genitalium,* and only 10.9% (5/46) became resistant to azithromycin treatment, in contrast with 89.6% (60/67) reported by Martens et al. We suggest that the decrease in macrolide resistance resulted from the increased number of posttreatment follow-ups. Our data confirm this. We believe that giving local advice on the basis of extended azithromycin treatment and posttreatment follow-up can limit the spread of macrolide resistance.
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